Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2017-06-30 Call Transcript
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 29, 2017, for Moleculin Biotech, Inc. It reports that the company held a live conference call on that date and is furnishing the conference call script as Exhibit 99.1. The text explicitly states that the document includes the conference call script, which is a full transcript or script of the call. There is no indication that this is merely an announcement or a summary; it is the actual script of the call. Therefore, this document fits the definition of a Call Transcript (CT). The document length is 2885 characters, which is consistent with a transcript or script rather than a brief announcement. Hence, the classification is CT with high confidence.
2017-06-30 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the conversion of convertible notes into common stock, which is a financing/capital structure update. It also references press releases about research developments, but these are attached as exhibits and are not the main report. The document does not contain comprehensive financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). The primary focus is on the unregistered sales of equity securities and the conversion of notes into shares, which fits the Capital/Financing Update category. Therefore, the correct classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information, not just an announcement of a report, so it is not RPA or RNS.
2017-06-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text mentions a press release about preparing to file an IND with the FDA, and the press release is attached as Exhibit 99.1. There are no detailed financial statements or comprehensive financial data presented in the document itself. The document is relatively short (3528 characters) and primarily serves as an announcement of a press release rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-13 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 25, 2017, by Moleculin Biotech, Inc. It reports on several items: entry into a material definitive agreement (an indemnification agreement with directors and officers), and submission of matters to a vote of security holders at the 2017 Annual Meeting of Stockholders. The document includes detailed voting results for proposals including election of directors, ratification of auditors, approval of a reverse stock split, and authorization to adjourn the meeting if needed. The presence of detailed voting results from the Annual Meeting clearly indicates this is a Declaration of Voting Results & Voting Rights Announcement. The document is not a full annual report, audit report, or earnings release, but a current report focused on shareholder voting outcomes and a material agreement. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements). The document length (7004 characters) and content support this classification with high confidence.
2017-05-31 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a proxy solicitation. It includes a letter to shareholders updating them on company activities, FDA designations, clinical trial progress, and fundraising. The document is not an annual report, earnings release, or financial report but rather a communication to shareholders typically associated with proxy materials. The SEC header and form type DEFA14A confirm it is a definitive additional proxy material. Therefore, the document fits the Remuneration Information (DEF 14A) category, which covers reports detailing compensation and related shareholder communications filed as proxy statements or amendments.
2017-05-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 23, 2017, by Moleculin Biotech, Inc. It announces the issuance of a press release containing a business update letter to shareholders. The document explicitly states that the information is incorporated by reference and is not considered "filed" for certain legal purposes. The content is primarily an announcement of a business update and financial condition results, not a full financial report or detailed earnings release. The document length is 3550 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or comprehensive analysis present. Therefore, this filing is best classified as a Regulatory Filing (RNS), which serves as a general regulatory announcement and fallback category for filings that do not fit other specific categories.
2017-05-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.